Amgen Inc.: enforcement record and regulatory exposure
Amgen Inc. scores 42 out of 100 on the RedFlag Index™ (October 2026), ranking #9 of ten tracked companies, with 3 documented cases of which 2 remain open.
Documented record
2019: Amgen paid $24.75 million over allegations that its copay-charity donations were kickbacks for Sensipar and Kyprolis.
2015: Amgen paid $71 million to 48 states and D.C. over off-label marketing of Enbrel and Aranesp.
2012: Amgen paid $762 million and pleaded guilty to misbranding Aranesp, including a $136 million criminal fine.
RegulationWatch coverage
- False Claims Act
Amgen pleaded guilty over Aranesp and paid $762 million. Then it kept paying.
The 2012 plea is a criminal conviction. Further settlements followed within months and continued for years.
- Merger Conditions
Amgen remains bound by FTC bundling ban from Horizon Therapeutics acquisition
The FTC finalised a consent order resolving its challenge, joined by six states, to Amgen's $27.8 billion acquisition of Horizon Therapeutics. The order bars Amgen from bundling its products with Horizon's Tepezza and Krystexxa, requires prior approval for related acquisitions and imposes 15-year compliance obligations under a monitor.
